At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...
Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback